Targeting targeted agents: open issues for clinical trial design

por Bria, Emilio, Di Maio, Massimo, Carlini, Paolo, Cuppone, Federica, Giannarelli, Diana, Cognetti, Francesco, Milella, Michele
Publicado 2009

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

por Loupakis, Fotios, Bria, Emilio, Vaccaro, Vanja, Cuppone, Federica, Milella, Michele, Carlini, Paolo, Cremolini, Chiara, Salvatore, Lisa, Falcone, Alfredo, Muti, Paola, Sperduti, Isabella, Giannarelli, Diana, Cognetti, Francesco
Publicado 2010

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma,...

por Carbognin, Luisa, Pilotto, Sara, Milella, Michele, Vaccaro, Vanja, Brunelli, Matteo, Caliò, Anna, Cuppone, Federica, Sperduti, Isabella, Giannarelli, Diana, Chilosi, Marco, Bronte, Vincenzo, Scarpa, Aldo, Bria, Emilio, Tortora, Giampaolo
Publicado 2015

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials

por Cuppone, Federica, Bria, Emilio, Giannarelli, Diana, Vaccaro, Vanja, Milella, Michele, Nisticò, Cecilia, Ruggeri, Enzo Maria, Sperduti, Isabella, Bracarda, Sergio, Pinnarò, Paola, Lanzetta, Gaetano, Muti, Paola, Cognetti, Francesco, Carlini, Paolo
Publicado 2010

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

por Cuppone, Federica, Bria, Emilio, Vaccaro, Vanja, Puglisi, Fabio, Fabi, Alessandra, Sperduti, Isabella, Carlini, Paolo, Milella, Michele, Nisticò, Cecilia, Russillo, Michelangelo, Papaldo, Paola, Ferretti, Gianluigi, Aapro, Matti, Giannarelli, Diana, Cognetti, Francesco
Publicado 2011